Wednesday October 9, 2019
1-5pm
San Francisco, CA
12:00-12:59 | Registration/Buffet Lunch |
13:00-13:02 | Kourous A. Rezaei, MD Welcome |
MODERATORS | |
Adrienne Graves, PhD Former Chief Executive Officer of Santen |
|
Kourous A. Rezaei, MD | |
13:03-13:08 | Guangping Gao, PhD President, American Society of Gene & Cell Therapy, Director of Horae Gene Therapy Center, Director of Research Institute for Rare Diseases, Professor, Microbiology & Physiological Systems, University of Massachusetts Medical School AAV Gene Therapy for Eye Diseases |
13:09-13:14 | Daniel C. Chung, DO, MA Global Medical Strategy Lead – Ophthalmology, Spark Therapeutic Clinical Development of Voretigene Neparvovec-ryzl, a gene therapy for Biallelic RPE65 Mutation-associated Inherited Retinal Disease: An Update |
13:15-13:20 | Tuyen Ong Head of Ophthalmology Franchise, Biogen Biogen Pipeline Update |
13:21-13:26 | Sue Washer President and Chief Executive Officer, Applied Genetic Technologies Corp. AGTC Update on Clinical and Research Programs |
13:27-13:32 | Kali Stasi, MD, PhD Translational Medicine Director, Novartis Institutes for BioMedical Research Novartis Retinal Gene Therapy Update |
13:33-13:40 | Discussion |
13:41-13:51 | Panel Wiley Chambers, MD; Pravin Dugel, MD; Hannah Chang, MD, PhD; Gilbert Kliman, MD; Eugene de Juan, MD |
MODERATORS: Karl Csaky, MD, PhD and Kourous A. Rezaei, MD | |
13:52-13:57 | Nader Halim, PhD Vice President, Strategy, Verana Health Accelerating Inherited Disease Trials with Data Insights |
13:58-14:03 | Mark Pennesi, MD, PhD Division Chief, Ophthalmic Genetics, Casey Eye Institute, Oregon Health & Science University Gene Therapy in the Real World |
14:04-14:09 | Andreas K. Lauer, MD Chair, Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University Subretinal Surgery for Gene Therapy: Lessons Learned |
14:10-14:15 | Jacque L. Duncan, MD Professor of Ophthalmology, University of California, San Francisco Outcome Measures for Gene Therapy Clinical Trials |
14:16-14:21 | K. Thiran Jayasundera, MD Associate Professor, Ophthalmology and Visual Sciences, Paul R. Lichter Professor of Ophthalmic Genetics University of Michigan Kellogg Eye Center Reported Patient Outcomes for Clinical Trials |
14:22-14:27 | Christine Nichols Kay, MD Vitreo Retinal Associates, Gainesville, Florida Genetic Testing: Real World Experience |
14:28-14:33 | Karl G. Csaky, MD, PhD Gene Therapy: Lessons Learned & the Road Ahead |
14:34-14:41 | Discussion |
14:42-14:52 | Panel Cyrus Mozayeni, MD; Karl Csaky, MD, PhD; Guangping Gao, PhD; Adrienne Graves, PhD |
MODERATORS: Adrienne Graves, PhD and Kourous A. Rezaei, MD | |
14:53-14:58 | Aaron Osborne Chief Medical Officer, Adverum Biotechnologies ADVM-022, a Novel Gene Therapy in Development for Wet AMD |
14:59-15:04 | Glenn P. Sblendorio Chief Executive Officer and President, IVERIC bio IVERIC bio Gene Therapy Pipeline |
15:05-15:10 | Susan Hill Chief Business Officer, Gyroscope Therapeutics Gyroscope: Gene Therapy Beyond Rare Disease |
15:11-15:16 | Francisco J. López, MD, PhD Executive Medical Director, Clinical Development Ophthalmology Allergan Retinal Gene Therapy programs at Allergan |
15:17-15:22 | Ken Mills President and Chief Executive Officer, REGENXBIO REGENXBIO: Driving Progress with Gene Therapy towards Transforming |
15:23-15:28 | Magali Taiel, MD Vice President of Clinical Development, Gensight GS010, a Novel Gene Therapy for Leber Hereditary Optic Neuropathy |
15:29-15:34 | Pete Adamson Vice President, Head, Retinal Disease Area Stronghold, Janssen Establishing Janssen’s Newest Leadership Area: Retinal Gene Therapy |
15:35-15:42 | Discussion |
MODERATORS: Eugene de Juan, MD and Kourous A. Rezaei, MD | |
15:43-15:50 | Wiley Chambers, MD Deputy director of the Division of Transplant and Ophthalmology Products, Food and Drug Administration Gene Therapy-Regulatory Perspective |
15:51-15:56 | Christine Placet Chief Executive Officer, Horama Horama Pipeline Update |
15:57-16:02 | Christopher Brittain Global Head of Ophthalmology Clinical Development, Genentech, Division of Roche Holding Roche Gene Therapy Update |
16:03-16:08 | Benjamin Yerxa, PhD Chief Executive Officer, Foundation Fighting Blindness Role of FFB in Advancing Gene Therapy for Orphan Retinal Diseases |
16:09-16:14 | Mark Vezina Scientific Director, Ocular and Neuroscience, Charles River Laboratories Animal Models in Gene Therapy |
16:15-16:20 | Deborah Wild Chief of Staff and VP of Corporate Development, Catalent Biologics, Paragon Gene Therapy Challenges in Gene Therapy Manufacturing |
16:21-16:28 | Discussion |
16:29-16:31 | Kourous A. Rezaei, MD Final Remarks |
16:32-17:30 | Networking |
12:30-12:59 | Registration |
13:00-13:02 | Kourous A. Rezaei, MD Welcome |
MODERATORS | |
Adrienne Graves, PhD Former Chief Executive Officer of Santen |
|
Kourous A. Rezaei, MD | |
13:03-13:08 | Guangping Gao, PhD President, American Society of Gene & Cell Therapy, Director of Horae Gene Therapy Center, Director of Research Institute for Rare Diseases, Professor, Microbiology & Physiological Systems, University of Massachusetts Medical School AAV Gene Therapy for Eye Diseases |
13:09-13:14 | Daniel C. Chung, DO, MA Global Medical Strategy Lead – Ophthalmology, Spark Therapeutic Clinical Development of Voretigene Neparvovec-ryzl, a gene therapy for Biallelic RPE65 Mutation-associated Inherited Retinal Disease: An Update |
13:15-13:20 | Tuyen Ong Head of Ophthalmology Franchise, Biogen Biogen Pipeline Update |
13:21-13:26 | Sue Washer President and Chief Executive Officer, Applied Genetic Technologies Corp. AGTC Update on Clinical and Research Programs |
13:27-13:32 | Kali Stasi, MD, PhD Translational Medicine Director, Novartis Institutes for BioMedical Research Novartis Retinal Gene Therapy Update |
13:33-13:40 | Discussion |
13:41-13:51 | Panel Pravin Dugel, MD; Hannah Chang, MD, PhD; Gilbert Kliman, MD; Eugene de Juan, MD |
MODERATORS: Karl Csaky, MD, PhD and Kourous A. Rezaei, MD | |
13:52-13:57 | Nader Halim, PhD Vice President, Strategy, Verana Health Accelerating Inherited Disease Trials with Data Insights |
13:58-14:03 | Mark Pennesi, MD, PhD Division Chief, Ophthalmic Genetics, Casey Eye Institute, Oregon Health & Science University Gene Therapy in the Real World |
14:04-14:09 | Andreas K. Lauer, MD Chair, Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University Subretinal Surgery for Gene Therapy: Lessons Learned |
14:10-14:15 | Jacque L. Duncan, MD Professor of Ophthalmology, University of California, San Francisco Outcome Measures for Gene Therapy Clinical Trials |
14:16-14:21 | K. Thiran Jayasundera, MD Associate Professor, Ophthalmology and Visual Sciences, Paul R. Lichter Professor of Ophthalmic Genetics University of Michigan Kellogg Eye Center Reported Patient Outcomes for Clinical Trials |
14:22-14:27 | Christine Nichols Kay, MD Vitreo Retinal Associates, Gainesville, Florida Genetic Testing: Real World Experience |
14:28-14:33 | Karl G. Csaky, MD, PhD Gene Therapy: Lessons Learned & the Road Ahead |
14:34-14:41 | Discussion |
14:42-14:52 | Panel Cyrus Mozayeni, MD; Karl Csaky, MD, PhD; Guangping Gao, PhD; Adrienne Graves, PhD |
MODERATORS: Adrienne Graves, PhD and Kourous A. Rezaei, MD | |
14:53-14:58 | Aaron Osborne Chief Executive Officer, Adverum Biotechnologies ADVM-022, a Novel Gene Therapy in Development for Wet AMD |
14:59-15:04 | Glenn P. Sblendorio Chief Executive Officer and President, IVERIC bio IVERIC bio Gene Therapy Pipeline |
15:05-15:10 | Susan Hill Executive Medical Director, Clinical Development Ophthalmology Allergan Retinal Gene Therapy programs at Allergan |
15:11-15:16 | Francisco J. López, MD, PhD President and Chief Executive Officer, Meira GTx Meira GTx IRD Pipeline Update |
15:17-15:22 | Ken Mills President and Chief Executive Officer, REGENXBIO REGENXBIO: Driving Progress with Gene Therapy towards Transforming |
15:23-15:28 | Magali Taiel, MD Vice President of Clinical Development, Gensight GS010, a Novel Gene Therapy for Leber Hereditary Optic Neuropathy |
15:29-15:34 | Pete Adamson Vice President, Head, Retinal Disease Area Stronghold, Janssen Establishing Janssen’s Newest Leadership Area: Retinal Gene Therapy |
15:35-15:42 | Discussion |
MODERATORS: Eugene de Juan, MD and Kourous A. Rezaei, MD | |
15:43-15:50 | Wiley Chambers, MD Deputy director of the Division of Transplant and Ophthalmology Products, Food and Drug Administration Gene Therapy-Regulatory Perspective |
15:51-15:56 | Christine Placet Chief Executive Officer, Horama Horama Pipeline Update |
15:57-16:02 | Christopher Brittain Global Head of Ophthalmology Clinical Development, Genentech, Division of Roche Holding Roche Gene Therapy Update |
16:03-16:08 | Benjamin Yerxa, PhD Chief Executive Officer, Foundation Fighting Blindness Role of FFB in Advancing Gene Therapy for Orphan Retinal Diseases |
16:09-16:14 | Mark Vezina Scientific Director, Ocular and Neuroscience, Charles River Laboratories Animal Models in Gene Therapy |
16:15-16:20 | Deborah Wild Chief of Staff and VP of Corporate Development, Catalent Biologics, Paragon Gene Therapy Challenges in Gene Therapy Manufacturing |
16:21-16:28 | Discussion |
16:29-16:31 | Kourous A. Rezaei, MD Final Remarks |
16:2-17:30 | Networking |